Advertisement

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Elias Jabbour, Nicholas J. Short, Guillermo Montalban-Bravo, Xuelin Huang, Carlos Bueso-Ramos, Wei Qiao, Hui Yang, Chong Zhao, Tapan Kadia, Gautam Borthakur, Naveen Pemmaraju, Koji Sasaki, Zeev Estrov, Jorge Cortes, Farhad Ravandi, Yesid Alvarado, Rami Komrokji, Mikkael A. Sekeres, David P. Steensma, Amy DeZern, Gail Roboz, Hagop Kantarjian and Guillermo Garcia-Manero

Article Information

Citation 
vol. 130 no. 13 1514-1522
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted May 31, 2017
  • Accepted July 24, 2017
  • Published online September 28, 2017.

Article Versions


Contributors 
  • Elias Jabbour, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Nicholas J. Short, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Guillermo Montalban-Bravo, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Xuelin Huang, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Carlos Bueso-Ramos, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Wei Qiao, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Hui Yang, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Chong Zhao, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Tapan Kadia, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Gautam Borthakur, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Naveen Pemmaraju, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Koji Sasaki, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Zeev Estrov, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Jorge Cortes, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Farhad Ravandi, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Yesid Alvarado, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Rami Komrokji, 2Moffitt Cancer Center, Tampa, FL;
  • Mikkael A. Sekeres, 3Cleveland Clinic, Cleveland, OH;
  • David P. Steensma, 4Dana-Farber Cancer Institute, Boston, MA;
  • Amy DeZern, 5Johns Hopkins University, Baltimore, MD; and
  • Gail Roboz, 6Cornell Medical College, New York, NY
  • Hagop Kantarjian, 1The University of Texas MD Anderson Cancer Center, Houston, TX;
  • Guillermo Garcia-Manero, 1The University of Texas MD Anderson Cancer Center, Houston, TX;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output